PURPOSE: Desmoplastic small round cell tumor (DSCRT) is an uncommon pediatric tumor with a poor prognosis. Aggressive multimodality therapy is the current treatment approach; however. treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation therapy (WAP-IMRT) as a component of multimodality therapy for DSCRT at a single institution. MATERIALS/ METHODS: Medical records of all patients with DSCRT who received WAP-IMRT as part of definitive treatment at MD Anderson (2006-2010) were identified and reviewed. RESULTS: Eight patients with DSRCT received WAP-IMRT with a median follow-up of 15.2 months. All patients received multiple courses of chemotherapy followed by surgical debulking of intra-abdominal disease; seven also had intraoperative hyperthermic cisplatin. WAP-IMRT was delivered to a total dose of 30 Gy postoperatively; four patients received a simultaneous boost (6-10 Gy) to sites of gross residual disease. Seven patients received concurrent chemotherapy during WAP-IMRT. No Radiation Therapy Oncology Group Grade 4 nausea, vomiting, or diarrhea occurred during RT. Red-cell transfusions were given to two patients to maintain hemoglobin levels >10 g/dL. Grade 4 cytopenia requiring growth factor support occurred in only one patient; no other significant cytopenias were noted. WAP-IMRT resulted in 25% lower radiation doses to the lumbosacral vertebral bodies and pelvic bones than conventional RT plans. The median time to local or distant failure after WAP-IMRT was 8.73 months in seven patients. One patient who had completed RT 20 months before the last follow-up remains alive without evidence of disease. Five patients (63%) experienced treatment failure in the abdomen. Distant failure occurred in three patients (37.5%). CONCLUSIONS: WAP-IMRT with concurrent radiosensitizing chemotherapy was well tolerated after aggressive surgery for DSCRT. Enhanced bone sparing with IMRT probably accounts for the low hematologic toxicity (vs. conventional WAP-RT). This modality should be considered as an additional local-regional control option for DSRCT.
PURPOSE:Desmoplastic small round cell tumor (DSCRT) is an uncommon pediatric tumor with a poor prognosis. Aggressive multimodality therapy is the current treatment approach; however. treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation therapy (WAP-IMRT) as a component of multimodality therapy for DSCRT at a single institution. MATERIALS/ METHODS: Medical records of all patients with DSCRT who received WAP-IMRT as part of definitive treatment at MD Anderson (2006-2010) were identified and reviewed. RESULTS: Eight patients with DSRCT received WAP-IMRT with a median follow-up of 15.2 months. All patients received multiple courses of chemotherapy followed by surgical debulking of intra-abdominal disease; seven also had intraoperative hyperthermic cisplatin. WAP-IMRT was delivered to a total dose of 30 Gy postoperatively; four patients received a simultaneous boost (6-10 Gy) to sites of gross residual disease. Seven patients received concurrent chemotherapy during WAP-IMRT. No Radiation Therapy Oncology Group Grade 4 nausea, vomiting, or diarrhea occurred during RT. Red-cell transfusions were given to two patients to maintain hemoglobin levels >10 g/dL. Grade 4 cytopenia requiring growth factor support occurred in only one patient; no other significant cytopenias were noted. WAP-IMRT resulted in 25% lower radiation doses to the lumbosacral vertebral bodies and pelvic bones than conventional RT plans. The median time to local or distant failure after WAP-IMRT was 8.73 months in seven patients. One patient who had completed RT 20 months before the last follow-up remains alive without evidence of disease. Five patients (63%) experienced treatment failure in the abdomen. Distant failure occurred in three patients (37.5%). CONCLUSIONS: WAP-IMRT with concurrent radiosensitizing chemotherapy was well tolerated after aggressive surgery for DSCRT. Enhanced bone sparing with IMRT probably accounts for the low hematologic toxicity (vs. conventional WAP-RT). This modality should be considered as an additional local-regional control option for DSRCT.
Authors: Tristan D Yan; Gary Edwards; Robert Alderman; Christina E Marquardt; Paul H Sugarbaker Journal: Ann Surg Oncol Date: 2006-10-10 Impact factor: 5.344
Authors: G Biswas; S Laskar; S D Banavali; S Gujral; P A Kurkure; M Muckaden; P M Parikh; Chandrika N Nair Journal: Indian J Cancer Date: 2005 Apr-Jun Impact factor: 1.224
Authors: W L Gerald; M Ladanyi; E de Alava; M Cuatrecasas; B H Kushner; M P LaQuaglia; J Rosai Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: Andrew L Feldman; Steven K Libutti; James F Pingpank; David L Bartlett; Tatiana H Beresnev; Sharon M Mavroukakis; Seth M Steinberg; David J Liewehr; David E Kleiner; H Richard Alexander Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig Journal: Curr Treat Options Oncol Date: 2009-06-17
Authors: Eelco de Bree; John Romanos; John Michalakis; Kostantinos Relakis; Vasilis Georgoulias; John Melissas; Dimitris D Tsiftsis Journal: Anticancer Res Date: 2003 May-Jun Impact factor: 2.480
Authors: Bridget F Koontz; Edward F Miles; Mary Ann D Rubio; John F Madden; Samuel R Fisher; Richard L Scher; David M Brizel Journal: Head Neck Date: 2008-02 Impact factor: 3.147
Authors: Paul H Sugarbaker; Robert Alderman; Gary Edwards; Christina Ellen Marquardt; Vadim Gushchin; Jesus Esquivel; David Chang Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Zachary E Stiles; Andrew J Murphy; Doralina L Anghelescu; Christina-Lin Brown; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Michael W Bishop; Wayne L Furman; Alberto S Pappo; John T Lucas; Jeremiah L Deneve Journal: Ann Surg Oncol Date: 2019-04-08 Impact factor: 5.344
Authors: Kevin X Liu; Natalie B Collins; Katie A Greenzang; Elissa Furutani; Kevin Campbell; Andrew Groves; Elizabeth A Mullen; Suzanne Shusterman; Jennifer Spidle; Karen J Marcus; Brent R Weil; Christopher B Weldon; A Lindsay Frazier; Katherine A Janeway; Allison F O'Neill; Jennifer W Mack; Steven G DuBois; David S Shulman Journal: Pediatr Blood Cancer Date: 2020-07-19 Impact factor: 3.167
Authors: Vivek Subbiah; Salah-Eddine Lamhamedi-Cherradi; Branko Cuglievan; Brian A Menegaz; Pamela Camacho; Winston Huh; Vandhana Ramamoorthy; Pete M Anderson; Raphael E Pollock; Dina C Lev; Wei Qiao; Mary Frances McAleer; Robert S Benjamin; Shreyaskumar Patel; Cynthia E Herzog; Najat C Daw; Barry W Feig; Alexander J Lazar; Andrea Hayes-Jordan; Joseph A Ludwig Journal: Clin Cancer Res Date: 2018-06-05 Impact factor: 12.531
Authors: Whitney L Guerrero; Gitonga Munene; Paxton V Dickson; Dina Darby; Andrew M Davidoff; Michael G Martin; Evan S Glazer; David Shibata; Jeremiah L Deneve Journal: J Gastrointest Oncol Date: 2018-04
Authors: Koichi Ogura; Romel Somwar; Julija Hmeljak; Lee Spraggon; Marc Ladanyi; Heather Magnan; Ryma Benayed; Amir Momeni Boroujeni; Anita S Bowman; Marissa S Mattar; Inna Khodos; Elisa de Stanchina; Achim Jungbluth; Marina Asher; Igor Odintsov; Alifiani B Hartono; Michael P LaQuaglia; Emily Slotkin; Christine A Pratilas; Sean Bong Lee Journal: Clin Cancer Res Date: 2020-11-23 Impact factor: 13.801